{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:21:05Z","timestamp":1788524465862,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["POSTD245952LABI"],"award-info":[{"award-number":["POSTD245952LABI"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["CLJUN234885LECU"],"award-info":[{"award-number":["CLJUN234885LECU"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020082","name":"Direcci\u00f3n General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra","doi-asserted-by":"publisher","award":["AGATA 0011-1411-2020-000010"],"award-info":[{"award-number":["AGATA 0011-1411-2020-000010"]}],"id":[{"id":"10.13039\/501100020082","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Department of Government of Navarre","award":["Intensification Scholarship 2024"],"award-info":[{"award-number":["Intensification Scholarship 2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58101-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:26:25Z","timestamp":1781742385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Ibone","family":"Labiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Guerrero-Setas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elsa","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorka","family":"Alkorta-Aranburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo R","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Lecumberri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Termini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Agirre-Mikelarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Arasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"58101_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA. Cancer J. Clin."},{"key":"58101_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s, G. et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291\u20131305 (2020).","journal-title":"Ann. Oncol."},{"key":"58101_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter, N. N. et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 40, 892\u2013910 (2022).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"58101_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","volume":"36","author":"R-D Hofheinz","year":"2025","unstructured":"Hofheinz, R.-D. et al. Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 36, 1007\u20131024 (2025).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"58101_CR5","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"58101_CR6","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.24.00648","volume":"43","author":"J Taieb","year":"2025","unstructured":"Taieb, J. et al. Combined analyses of circulating tumor DNA and immunoscore in patients with stage III colon cancer: a post Hoc analysis of the PRODIGE-GERCOR IDEA-France\/HORG-IDEA-greece TRIALS. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 43, 1564\u20131577 (2025).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"58101_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"58101_CR8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. & Chabner, B. A. Application of Cell-free DNA Analysis to Cancer Treatment. N. Engl. J. Med. 379, 1754\u20131765 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58101_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-026-01126-1","volume":"23","author":"G Martini","year":"2026","unstructured":"Martini, G. et al. Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling. Nat. Rev. Clin. Oncol. 23, 356\u2013373 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"58101_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari, A. et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol. 17, 757\u2013770 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"58101_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","volume":"36","author":"B Mart\u00ednez-Castedo","year":"2025","unstructured":"Mart\u00ednez-Castedo, B. et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Ann. Oncol. 36, 263\u2013276 (2025).","journal-title":"Ann. Oncol."},{"key":"58101_CR12","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"58101_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","volume":"35","author":"TV Henriksen","year":"2024","unstructured":"Henriksen, T. V. et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35, 229\u2013239 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"58101_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9\u201316 (2015).","journal-title":"Blood"},{"key":"58101_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s12885-020-07445-5","volume":"20","author":"S Verma","year":"2020","unstructured":"Verma, S. et al. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma. BMC Cancer 20, 945 (2020).","journal-title":"BMC Cancer"},{"key":"58101_CR16","first-page":"986","volume":"24","author":"P Horak","year":"2022","unstructured":"Horak, P. et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet. Med. Off. J. Am. Coll. Med. Genet. 24, 986\u2013998 (2022).","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"58101_CR17","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-24-3335","volume":"31","author":"D Magee","year":"2025","unstructured":"Magee, D. et al. Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients. Clin. Cancer Res. 31, 2710\u20132718 (2025).","journal-title":"Clin. Cancer Res."},{"key":"58101_CR18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.12727","volume":"14","author":"HT Chan","year":"2020","unstructured":"Chan, H. T. et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol. Oncol. 14, 1719\u20131730 (2020).","journal-title":"Mol. Oncol."},{"key":"58101_CR19","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi, P. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928\u20131937 (2019).","journal-title":"Nat. Med."},{"key":"58101_CR20","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","volume":"8","author":"MG Krebs","year":"2022","unstructured":"Krebs, M. G. et al. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. JAMA Oncol. 8, 1830\u20131839 (2022).","journal-title":"JAMA Oncol."},{"key":"58101_CR21","doi-asserted-by":"publisher","first-page":"102051","DOI":"10.1016\/j.esmoop.2023.102051","volume":"8","author":"F Gimeno-Valiente","year":"2023","unstructured":"Gimeno-Valiente, F. et al. Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. ESMO Open 8, 102051 (2023).","journal-title":"ESMO Open"},{"key":"58101_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clinbiochem.2021.03.005","volume":"92","author":"F Huang","year":"2021","unstructured":"Huang, F. et al. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS\/NRAS\/BRAF genotyping for metastatic colorectal cancer. Clin. Biochem. 92, 46\u201353 (2021).","journal-title":"Clin. Biochem."},{"key":"58101_CR23","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona, N. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30, 1804\u20131812 (2019).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"58101_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","volume":"14","author":"G Chen","year":"2021","unstructured":"Chen, G. et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J. Hematol. Oncol. 14, 80 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"58101_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"58101_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2022).","journal-title":"Clin. Cancer Res."},{"key":"58101_CR27","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin. Cancer Res Off. J. Am. Assoc. Cancer Res. 27, 5586\u20135594 (2021).","journal-title":"Clin. Cancer Res Off. J. Am. Assoc. Cancer Res."},{"key":"58101_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04030-w","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04030-w (2025).","journal-title":"Nat. Med."},{"key":"58101_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw332","volume":"109","author":"L Zhang","year":"2017","unstructured":"Zhang, L. & Shay, J. W. Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer. J. Natl. Cancer Inst. 109, djw332 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"58101_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"58101_CR31","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","volume":"30","author":"S Slater","year":"2024","unstructured":"Slater, S. et al. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC part B study. Clin. Cancer Res. 30, 3459\u20133469 (2024).","journal-title":"Clin. Cancer Res."},{"key":"58101_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","volume":"9","author":"S Mo","year":"2023","unstructured":"Mo, S. et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 9, 770\u2013778 (2023).","journal-title":"JAMA Oncol."},{"key":"58101_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"58101_CR34","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.3390\/cancers15133301","volume":"15","author":"F Moratalla-Navarro","year":"2023","unstructured":"Moratalla-Navarro, F. et al. Identification of a twelve-microRNA signature with prognostic value in stage II microsatellite stable colon cancer. Cancers 15, 3301 (2023).","journal-title":"Cancers"},{"key":"58101_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-026-02624-7","volume":"25","author":"K Miyazaki","year":"2026","unstructured":"Miyazaki, K. et al. An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study. Mol. Cancer 25, 136 (2026).","journal-title":"Mol. Cancer"},{"key":"58101_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","volume":"28","author":"MG Best","year":"2015","unstructured":"Best, M. G. et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666\u2013676 (2015).","journal-title":"Cancer Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58101-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58101-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58101-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:02:52Z","timestamp":1788523372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58101-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58101-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IL, AEH, EM, GAA, GRO, PB, OP, IC, RT, BAM and IA have no conflicts of interest. AL has received support for attending meetings and\/or travel from MSD, Merck, Seagen, Novartis and BeOne Medicines. NC declares speaker honoraria from Pierre-Fabre and Roche. HA has received honoraria for advisory role from Roche, Pfizer and Fundaci\u00f3n ECO; for clinical trial coordination from Ferrer Farma; for traveling\/accommodation expenses from BMS, MSD, Roche and Takeda. MA discloses advisory\/consultancy roles honoraria from Amgen, AstraZeneca, BeiGene, Dragonfly Therapeutics, Jazz Pharmaceuticals, BMS, Novartis and MSD; and speaker honoraria from Astellas, Beigene, Jazz Pharmaceuticals, MSD. RV has received honoraria for the advisory role and for speaking from Amgen, AstraZeneca, Merck, Roche, Sanofi, MSD, Servier, Takeda; consultant from Novartis, Biocartis, Lilly.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Research Ethics Committee of the HUN, in line with the ethical guidelines of the 1975 Declaration of Helsinki (sixth revision, 2008) as reflected in a priori approval by the institution\u2019s clinical research committee (PI_2020-118). Written informed consent was obtained for all patients.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27773"}}